The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 28, 2010
Filed:
Jul. 30, 2007
Te-wei Lee, Taipei, TW;
Chun-ying Huang, Taipei, TW;
Ming-shiuan Wu, Taipei, TW;
Te-jung Chen, Taoyuan, TW;
Kwo-ping Chang, Taoyuan, TW;
Shiang-rong Chang, Taoyuan, TW;
Shyh-yi Chyi, Taoyuan, TW;
Chih-hsien Chang, Hsinchu, TW;
Yin-mao Hsu, Taipei, TW;
Kuo-hsien Fan, Taichung, TW;
Wei-chuan Hsu, Miaoli, TW;
Ying-kai Fu, Taoyuan, TW;
Charng-feng Kao, Taipei, TW;
Te-Wei Lee, Taipei, TW;
Chun-Ying Huang, Taipei, TW;
Ming-Shiuan Wu, Taipei, TW;
Te-Jung Chen, Taoyuan, TW;
Kwo-Ping Chang, Taoyuan, TW;
Shiang-Rong Chang, Taoyuan, TW;
Shyh-Yi Chyi, Taoyuan, TW;
Chih-Hsien Chang, Hsinchu, TW;
Yin-Mao Hsu, Taipei, TW;
Kuo-Hsien Fan, Taichung, TW;
Wei-Chuan Hsu, Miaoli, TW;
Ying-Kai Fu, Taoyuan, TW;
Charng-Feng Kao, Taipei, TW;
Institute of Nuclear Energy Research Rocaec, Taoyuan, TW;
TTY Biopharm Company, Limited, Taipei, TW;
Abstract
This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of AsO, AsS, AsS, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i). This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.